Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05776979 · ClinicalTrials.gov registry record · Phase 2

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

A Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
61
Enrollment target
1
Study location

NCT05776979: Recruiting Phase 2 study of Multiple Myeloma, sponsored by M.D. Anderson Cancer Center.

NCT05776979 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 61 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05776979, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Isatuximab
  • DRUG lenalidomide

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2023-08-17
Est. Completion 2027-12-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05776979

The ClinicalTrials.gov registry entry for NCT05776979 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (89% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Isatuximab is the first listed.

NCT05776979 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05776979 about?

NCT05776979 is a clinical study titled "Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients". To learn if isatuximab can help to control highrisk MM when given in combination with lenalidomide after an autologous stem cell transplantation (ASCT).

What is the current status of trial NCT05776979?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2023-08-17. Estimated completion is 2027-12-31.

What conditions does trial NCT05776979 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT05776979?

The interventions under investigation include: Isatuximab (DRUG), lenalidomide (DRUG).

Who is sponsoring clinical trial NCT05776979?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05776979 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.